HLB Life ScienceHLB생명과학
067630 · KOSDAQ · ₩067630 · HLB생명과학
₩3,295▲ ₩15 (0.46%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −5.1% | −1.1% | −2.1% | −0.8% | −3.1% | −10.4% |
| Operating margin | −43.5% | −48.1% | −24.3% | −25.0% | −20.2% | −34.5% |
| Net margin | −60.9% | −218.1% | 6.0% | −6.1% | −54.5% | −91.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +18.9% | −55.3% | +4.3% | −1.6% | +86.2% | — |
| Operating income growth | −7.4% | +11.2% | −1.2% | −21.7% | −9.1% | — |
| Net income growth | +66.8% | −1,725.9% | +202.6% | +89.0% | −10.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −11.4% | −28.7% | 2.0% | −2.6% | −22.6% | −20.0% |
| Return on assets | −7.0% | −19.7% | 1.3% | −1.4% | −15.9% | −18.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 65.8% | 60.6% | 35.2% | 83.2% | 74.4% | 9.8% |
| Net debt to equity | 26.4% | 31.7% | 14.9% | 42.2% | 10.5% | −11.3% |
| Current ratio | 57.5% | 58.0% | 290.0% | 108.6% | 600.3% | 1,158.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: HLB Life Science / HLB생명과학 / 067630 / KRX:067630
Source: KRX statistical information